Denali Therapeutics Inc. financial data

Symbol
DNLI on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
161 Oyster Point Blvd., South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.05K % +34.5%
Debt-to-equity 9.67 % -48.2%
Return On Equity -31.4 % -132%
Return On Assets -28.6 % -151%
Operating Margin -65.5 % +83.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 145M shares +1.83%
Common Stock, Shares, Outstanding 144M shares +4.22%
Entity Public Float 1.9B USD -5%
Common Stock, Value, Issued 1.71M USD +1.48%
Weighted Average Number of Shares Outstanding, Basic 164M shares +19.7%
Weighted Average Number of Shares Outstanding, Diluted 164M shares +19.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 295M USD +191%
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 396M USD -6.47%
General and Administrative Expense 105M USD +2.02%
Operating Income (Loss) -487M USD -148%
Nonoperating Income (Expense) 51.5M USD +249%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -423M USD -191%
Earnings Per Share, Basic -2.57 USD/shares -142%
Earnings Per Share, Diluted -2.57 USD/shares -142%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 175M USD +37.6%
Marketable Securities, Current 657M USD -27.6%
Assets, Current 864M USD -18.8%
Property, Plant and Equipment, Net 55.2M USD +21.2%
Operating Lease, Right-of-Use Asset 22.9M USD -12.2%
Other Assets, Noncurrent 24.7M USD +36.4%
Assets 1.37B USD +19.1%
Accounts Payable, Current 11.1M USD +17.4%
Employee-related Liabilities, Current 24.7M USD +14.5%
Accrued Liabilities, Current 91.1M USD +33%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 102M USD +31.1%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 36.7M USD -18.5%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 144M USD +17.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.02M USD +214%
Retained Earnings (Accumulated Deficit) -1.54B USD -37.9%
Stockholders' Equity Attributable to Parent 1.23B USD +19.3%
Liabilities and Equity 1.37B USD +19.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -114M USD -93.2%
Net Cash Provided by (Used in) Financing Activities 500M USD +31089%
Net Cash Provided by (Used in) Investing Activities -453M USD -389%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 144M shares +4.22%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -66.5M USD +55.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 177M USD +37.2%
Deferred Tax Assets, Valuation Allowance 488M USD +29.8%
Deferred Tax Assets, Gross 504M USD +30%
Operating Lease, Liability 45M USD -13.9%
Payments to Acquire Property, Plant, and Equipment 2.15M USD -22.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -421M USD -206%
Lessee, Operating Lease, Liability, to be Paid 53.9M USD -17.5%
Property, Plant and Equipment, Gross 107M USD +17.1%
Operating Lease, Liability, Current 8.31M USD +14.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.2M USD +3.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 11.8M USD +3.29%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.96M USD -31.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.6M USD +3.3%
Deferred Tax Assets, Operating Loss Carryforwards 113M USD +27%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 40M shares 0%
Unrecognized Tax Benefits 33.8M USD +29%
Lessee, Operating Lease, Liability, to be Paid, Year Four 13M USD +3.31%
Operating Lease, Payments 11.4M USD +0.64%
Additional Paid in Capital 2.76B USD +28.9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.16M USD -78.5%
Deferred Tax Assets, Net of Valuation Allowance 16.3M USD +36.5%
Share-based Payment Arrangement, Expense 103M USD -4.83%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%